Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Thu, 17th Jun 2021 11:43

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Midatech Pharma PLC, up 89% at 51.90 pence, 12-month range 18.10p-87.00p. The biotechnology company says it has data demonstrating that its Q-Sphera technology can formulate monoclonal antibodies into long-acting injectables, a novel development in pharmaceuticals with significant medical and commercial potential. "The company believes no other commercial or academic organisation has been able to successfully deliver therapeutic proteins over extended periods using methods capable of commercial scaling," it says.

----------

Blue Prism Group PLC, up 7.4% at 964.50p, 12-month range 883.50p-1,900.00p. The robotic process automation firm posts narrowed interim loss after seeing growing revenue and booking numbers for the period. Blue Prism reports a pretax loss of GBP21.0 million for the six months ended April 30, sharply narrowed from GBP53.8 million a year prior. Bookings grew 35% in the first half to GBP98 million, or 39% at constant currency. Revenue for the period increased by 21% year-on-year to GBP80.4 million from GBP66.6 million, with recurring, subscription-based, licence revenue accounting for a 98% share.

----------

AIM - LOSERS

----------

Open Orphan PLC, down 14% at 30.00p, 12-month range 11.16p-34.50p. The pharmaceutical services company posts 2020 pretax loss GBP11.2 million, widened from GBP5.8 million on revenue from continuing operations of GBP20.6 million, up from GBP3.4 million. Separately, Poolbeg Pharma confirms plan to float on AIM as a spinoff of Open Orphan. Poolbeg Pharma to use IPO raise to fund clinical trial of treatment for severe influenza.

----------

Cake Box Holdings PLC, down 7.3% at 266.50p, 12-month range 155.00p-356.00p. The eggless deserts maker notes movement in shares. It confirms that it has recently emailed customers in relation to a data breach experienced in 2020 as a result of which personal and financial information may potentially have been accessed. Cake Box says it has taken the appropriate steps to investigate the incident, repair the compromised systems, and identify those customers that may have been compromised. It also has further strengthened the security of its systems to prevent future breaches, it says. "The company confirms that the data breach is not expected to have a material financial impact and as per the announcement on 12 April 2021, full year results are expected to be in line with market expectations," Cake Box adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.